SAVOR-TIMI 53 was a randomized, double-blind, placebo-controlled trial to assess the cardiovascular efficacy and safety of saxaglipitin, a DPP-4 inhibitor, when added to standard of care in patients with type 2 diabetes mellitus.
TIMI 53 Slides
HF Risk Stratification and Efficacy of SGLT2 Inhibitors in Patients with T2DM (Berg ESC 2019)
SAVOR DM Genetics (Marston AHA 2019)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
Response by Bergmark et al to Letter Regarding Article, “Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial”
Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial